TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03616496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuraceq PET/CT imaging
Description: PET/CT with Neuraceq injection, blood and urine sampling for protein electrophoresis, bone scintigraphy for the three arm (if the exams are present in the patient's medical record and are less than 3 months old, they do not need to be repeated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuraceq PET/CT imaging
Description: PET/CT with Neuraceq injection, blood and urine sampling for protein electrophoresis, bone scintigraphy for the three arm (if the exams are present in the patient's medical record and are less than 3 months old, they do not need to be repeated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuraceq PET/CT imaging
Description: PET/CT with Neuraceq injection, blood and urine sampling for protein electrophoresis, bone scintigraphy for the three arm (if the exams are present in the patient's medical record and are less than 3 months old, they do not need to be repeated
Study: NCT00694109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mipomersen Sodium
Description: Subcutaneous injection as a single injection directly into the abdomen, thigh, or outer area of the upper arm.
Study: NCT00534170

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (Yakult)
Description: It is a dietary supplement ,65 ml containing 15 billion lactobacillus
Study: NCT04351035

Intervention type: PROCEDURE
Intervention: Tumour resection
Description: It is mandatory that patients recieve surgical treatment for pathological diagnosis of CNS tumours in enrolled patients. Surgical resection of tumours could be regarded as total / subtotal / partial resection and biopsy.
Study: NCT02280876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 - Andrographis paniculata p/st extract
Description: Andrographis paniculata Extract (ApE), Oral tablets 650 mg, with 170 mg. of andrographolides active principles, three times per day, during a total of 365 continuous days.~Other Names:~• ApE tablets, EUROMED Specific. Santiago Chile.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2 - Excipients
Description: Placebo 650mg tabs, 2/day, 365 days continuously.~Other Names:~• Excipients tablets EUROMED Specific. Santiago Chile
Study: NCT04499612

Intervention type: PROCEDURE
Intervention: Cardiac implantable electronic device implantation.
Description: Patients who have indications will receive cardiac implantable electronic device implantation.
Study: NCT02780271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-communication
Description: 11 months of motivational text messages, emailed newsletters, and access to a website.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Written guidelines on diet and physical activity for breast cancer survivors, a pedometer to encourage physical activity, and a brief verbal overview of diet and physical activity guidelines for cancer survivors.
Study: NCT04499612

Intervention type: PROCEDURE
Intervention: Cardiac implantable electronic device implantation.
Description: Patients who have indications will receive cardiac implantable electronic device implantation.

Intervention type: PROCEDURE
Intervention: Cardiac implantable electronic device implantation.
Description: Patients who have indications will receive cardiac implantable electronic device implantation.

Intervention type: PROCEDURE
Intervention: Cardiac implantable electronic device replace.
Description: Patients who have indications will receive cardiac implantable electronic device replace.

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound.
Description: Patients will undergo ultrasound examination of the vessels of the upper and lower extremities.
Study: NCT02780271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Written guidelines on diet and physical activity for breast cancer survivors, a pedometer to encourage physical activity, and a brief verbal overview of diet and physical activity guidelines for cancer survivors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Written guidelines on diet and physical activity for breast cancer survivors, a pedometer to encourage physical activity, and a brief verbal overview of diet and physical activity guidelines for cancer survivors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Written guidelines on diet and physical activity for breast cancer survivors, a pedometer to encourage physical activity, and a brief verbal overview of diet and physical activity guidelines for cancer survivors.
Study: NCT03397602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard care + moderate-intensity continuous exercise training
Description: Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard care + high-intensity interval training
Description: Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
Study: NCT03021629

Intervention type: OTHER
Intervention: Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay

Intervention type: OTHER
Intervention: Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay

Intervention type: OTHER
Intervention: Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
Study: NCT03529214

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exposed study site
Description: The study sites will pilot the Team Birth Project designed to improve team communication (between providers, as well as providers and patients). The project includes three key implementation steps that involve: preparing local sites for the implementation of the project; training and coaching on the use of the tools; and sustainment through peer coaching and data feedback. A mixed methods approach will be used to assess acceptability and feasibility, including: (1) clinician surveys and interviews, (2) implementation team focus groups, and (3) patient surveys.
Study: NCT04283253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot + TTT exercise
Description: The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
Study: NCT04499612

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound.
Description: Patients will undergo ultrasound examination of the vessels of the upper and lower extremities.

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound.
Description: Patients will undergo ultrasound examination of the vessels of the upper and lower extremities.
Study: NCT00843011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orvepitant
Description: Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food.
Study: NCT00666159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus ointment
Description: topical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus cream
Description: topical
Study: NCT01290575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: capsule, Oral, 0.0mg, twice daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: capsule, Oral, 0.0mg, twice daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: capsule, Oral, 0.0mg, twice daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: capsule, Oral, 0.0mg, twice daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: capsule, Oral, 0.0mg, twice daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: capsule, Oral, 0.0mg, twice daily, 14 day
Study: NCT04499612

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound.
Description: Patients will undergo ultrasound examination of the vessels of the upper and lower extremities.

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound.
Description: Patients will undergo ultrasound examination of the vessels of the upper and lower extremities.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography.
Description: Patients will undergo an ultrasound examination of the heart.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography.
Description: Patients will undergo an ultrasound examination of the heart.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography.
Description: Patients will undergo an ultrasound examination of the heart.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography.
Description: Patients will undergo an ultrasound examination of the heart.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography.
Description: Patients will undergo an ultrasound examination of the heart.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling.
Description: Patients will be taken venous blood to determine the studied markers of hemostasis system.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling.
Description: Patients will be taken venous blood to determine the studied markers of hemostasis system.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling.
Description: Patients will be taken venous blood to determine the studied markers of hemostasis system.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling.
Description: Patients will be taken venous blood to determine the studied markers of hemostasis system.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling.
Description: Patients will be taken venous blood to determine the studied markers of hemostasis system.
Study: NCT02708407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis
Description: One week after insertion of a PD catheter the intervention group will received a single nightly exchange, using dialysis fluid containing icodextrin; a variable proportion of participants may require a second exchange as directed by the consultant nephrologist as part of routine care. The second exchange would use dialysis fluid containing glucose, not icodextrin. Support and training will be given to each participant by the PD specialist team.
Study: NCT03026075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motus Cleansing System (MCS)
Description: The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter \& fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
Study: NCT00972322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8245
Description: MK-8245 50 mg twice daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: matching placebo to MK-8245 twice daily for 28 days
Study: NCT02334579

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Stereotactic Radiosurgery
Description: Five treatments given over about one week.
Study: NCT01533753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
Study: NCT00566189

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Bypass Gastroplasty
Description: Under open laparotomy, a stomach section separates a 80-ml proximal gastric pouch. A jejunum section below Treitz's Angle creates an excluded gastrobiliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the continuity between the gastric pouch and the jejunum and a silastic ring reduces the pouch outlet.The anastomosis of the excluded limb is done 100cm below the silastic ring.
Study: NCT04004689

Intervention type: OTHER
Intervention: 2 times : 6-minute stepper test with a rest of 20min between each test.
Description: Patients will perform two 6-minute stepper tests separated by a rest period of at least 20 minutes. The second test will begin when the heart rate and the transcutaneous oxygen saturation values will be returned to baseline values. Standardization of the instructions for the test will be based on the actual guidelines for the 6-minute walk test.~The test will be performed in an isolated room in order to avoid noise or external stimuli which can affect performance. The stepper will be placed near a door and the patient was allowed to put a hand on it if out of balance or exhausted. The height of the step will be fixed to 20 cm. A step was defined as the rise and lowering of one foot. The patient was informed of the time each minute. No other encouragement was given. Heart rate and transcutaneous oxygen saturation will be continuously recorded by a pulse oximetry.
Study: NCT00218270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobacco free snuff
Description: Tobacco free snuff

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tobacco free snuff
Description: Tobacco free snuff
Study: NCT00271206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: compared to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Compared to progesterone
Study: NCT01008800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Communication
Description: The Center-Based classroom intervention focuses on providing children with an invigorating, motivating learning environment in which emerging skills and knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement week may offer the children experiences that they would not otherwise have (Ramey \& Ramey, 1998). Parent training sessions will focus on strategies aimed at improving child social engagement and communication and on topics related to autism characteristics, learning styles, interventions, and resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social communication
Description: Parent training sessions will focus on teaching parents strategies for enhancing their child's social engagement and communication. Since parents will be using these strategies across all activities throughout the day, there is an increased likelihood of generalization. For parents of minority and underserved children, this may be the first exposure to responsive interaction strategies (Rudy \& Grusec, 2001).
Study: NCT01372839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care

Intervention type: DRUG
Group type: OTHER
Intervention: Statin
Description: Usual care, but statin dose should not be higher than that described in exclusion criteria
Study: NCT02595580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucopred
Study: NCT01200290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 120 milligrams (mg) administered subcutaneously every 4 weeks for 20 weeks. A loading dose of 240 mg will be given as the first dose of the study medication
Study: NCT01681615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylate
Description: 1-2 drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic NaCl
Description: 1 drop
Study: NCT03350399

Intervention type: DIAGNOSTIC_TEST
Intervention: placenta growth factor
Description: estimation level of derum placenta growth factor
Study: NCT01217437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT00691249

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4-Raw
Description: Low Dose- 70g bar

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4-Raw
Description: High Dose- 100g bar

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4-Cooked
Description: Low Dose- 70g bar

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4-Cooked
Description: High dose: 100g bar

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Shredded Wheat
Description: 70g bar
Study: NCT05572593

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics (PGx) genetic testing
Description: A buccal swab to collect cells from the inside the cheek

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenomics (PGx) genetic testing
Description: A buccal swab to collect cells from the inside the cheek
Study: NCT02712489

Intervention type: OTHER
Intervention: No intervention
Study: NCT00958542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical fusion
Description: Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
Study: NCT02413281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablets, single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablets, single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablets, single administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Sublingual tablets, single administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Sublingual tablets, single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual tablets, single administration
Study: NCT01511341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telenursing
Description: The nurse-led intervention will consist of providing a monthly telephone call by a qualified and experienced nurse specialist in paediatric rheumatology and TN to ensure follow-up of the children and their family. The intervention will focus on providing affective support, health information, and aid to making decision.
Study: NCT04785105

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04116801

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microsurgical resection
Description: resection of cerebral metastases by microsurgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microsurgical resection
Description: resection of cerebral metastases by microsurgery
Study: NCT02222870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Description: 0.25 mL, Intramuscular (Pediatric Dose, 2014-2015 formulation)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Description: 0.5 mL, Intramuscular (2014-2015 formulation)
Study: NCT03008798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal Medicine C-117
Description: C117 formula including 2 herbals and 2 insects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The Placebo of Herbal Medicine C-117
Study: NCT02592876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denintuzumab mafodotin
Description: Denintuzumab mafodotin 3 mg/kg by intravenous (IV) infusion, every 3 weeks for up to 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 by IV infusion, every 3 weeks for up to 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m\^2 by IV infusion, every 3 weeks for up to 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: 5000 mg/m\^2 by IV infusion over a 24-hour period, every 3 weeks for up to 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide
Description: 5000 mg/m\^2 by IV infusion over a 24-hour period, every 3 weeks for up to 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5mg/mL x min by IV infusion, every 3 weeks for up to 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: AUC 5mg/mL x min by IV infusion, every 3 weeks for up to 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100 mg/m\^2 per day by IV infusion for 3 days, every 3 weeks for up to 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: 100 mg/m\^2 per day by IV infusion for 3 days, every 3 weeks for up to 3 cycles
Study: NCT01435772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMN 701
Description: GILT-tagged recombinant human GAA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMN 701
Description: GILT-tagged recombinant human GAA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMN 701
Description: GILT-tagged recombinant human GAA
Study: NCT01290575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, 0.0mg, once daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, 0.0mg, once daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, 0.0mg, once daily, 14 day